Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Macular Edema Clinical Trial

Official title:

A Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03739593
• Other study ID #: AR-1105-CS201
• Status: Completed
• Phase: Phase 2
• Start date: March 13, 2019
• Est. completion date: July 9, 2020

Study information

• Verified date: February 2022
• Source: Aerie Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, and potentially lower the incidence of steroid-related side effects without compromising efficacy.

Description:

AR-1105 is a dexamethasone containing implant drug delivery system that is injected into the back of the eye. It is designed to dissolve slowly over time, continuously releasing a consistent low dose of steroid to treat the symptoms of RVO and associated inflammation with a goal of halting further visual disturbance and damage, and also possibly restoring some vision as symptoms are controlled. In this study, 2 different formulations are being tested to find the optimum combination of efficacy, safety and durability that will offer patients a potential treatment option that is as safe and effective as the treatments currently available, but which requires less frequent injections and potentially has a lower risk for certain side-effects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: July 9, 2020
• Est. primary completion date: May 14, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. At least 18 years of age

2. Vision loss due to clinically detectable macular edema (ME) associated with either central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). Subjects may be treatment-naïve, or if previously-treated with a steroid, must have demonstrated response to treatment

3. Duration of macular edema (ME) =9 months in subjects with CRVO and =12 months in subjects with BRVO. If both eyes are eligible, the study eye will be the eye with worse VA

4. Best-corrected visual acuity (BCVA) as measured by the early treatment of diabetic retinopathy study (ETDRS) methodology of between 25 and 70 letters, in the study eye and better than 35 letters, in the non-study eye

5. Retinal thickness in the central subfield of >290 µm (females) and >305 µm (males) if using a Cirrus (Zeiss) instrument, or if a Spectralis (Heidelberg) instrument is used, thickness should be >305 µm (females) or >320 µm (males) in the study eye

6. Be able to understand and willing to provide written informed consent.

7. Be willing and able to adhere to the instructions set forth in the study protocol

Exclusion Criteria:

Ophthalmic:

1. Presence of a clinically significant epiretinal membrane, active retinal or optic disc neovascularization, active or history of choroidal neovascularization, presence of rubeosis iridis

2. History or presence of herpetic infection, toxoplasmosis, chorioretinopathy.

3. Subjects with moderate non-proliferative diabetic retinopathy or worse in either eye are excluded from participation

4. Any active infection

5. Aphakia, significant posterior capsule tear or iris trauma in the study eye

6. Anterior-chamber intraocular lens

7. Clinically significant media opacity

8. History of glaucoma or visual field loss

9. Ocular hypertension in the study eye at qualification, (with or without treatment)

10. History of corticosteroid-induced IOP increase in either eye

11. Ocular condition in the study eye that, in the opinion of the investigator, would prevent a 15-letter improvement in visual acuity

12. Received an intraocular steroid injection or implant within 6 months or any anti-VEGF treatment within 2 months prior to screening. Prior treatment with RETISERT® or ILUVIEN® or pan-retinal photocoagulation (PRP) is exclusionary

13. Intraocular surgery (including laser refractive or eyelid surgery) within 3 months prior to Visit 1 or anticipated need for ocular surgery or ophthalmic laser treatment during the study treatment period

14. Currently using topical corticosteroids in the vicinity of the eyes within the 1 month prior to Visit 1

15. Periocular depot of steroids placed within 6 months prior to qualification

16. Ocular medications that are specifically disallowed in this protocol for any condition during the study or within the specified timeframe prior to Visit 2

17. Have progressive optic nerve disease or retinal disease other than retinopathy due to RVO that affects BCVA

Systemic:

18. Currently using or anticipating the use of systemic corticosteroids during the study (with the exception of inhaled, intranasal or topical corticosteroids)

19. Any clinically significant or uncontrolled serious or severe medical or psychiatric condition

20. Participation in any other interventional clinical study within 30 days prior to Visit 1

21. History of hypersensitivity or poor tolerance to any components of the preparations to be used in this study such as dexamethasone or biodegradable polymer (PLGA) excipients or fluorescein

22. Systemic condition that may confound the study outcome per the investigator's opinion

23. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

Related Conditions & MeSH terms

• Edema
• Macular Edema
• Retinal Vein Occlusion

Intervention

Drug:
• AR-1105-CF1
AR-1105 clinical formulation 1 (AR-1105-CF1)
• AR-1105-CF2
AR-1105 clinical formulation 2 (AR-1105-CF2)

Locations

Country	Name	City	State
United States	Retina Research Institute of Texas	Abilene	Texas
United States	Florida Eye Clinic	Altamonte Springs	Florida
United States	Texas Retina Associates	Arlington	Texas
United States	Retina Vitreous Associates	Beverly Hills	California
United States	Mid-Atlantic Retina	Cherry Hill	New Jersey
United States	Cleveland Clinic- Cole Eye Institute	Cleveland	Ohio
United States	Center for Retina & Macular Disease	Lakeland	Florida
United States	Byers Eye Institute at Stanford	Palo Alto	California
United States	Retina Specialty Institute	Pensacola	Florida
United States	Retinal Research Institute, LLC	Phoenix	Arizona
United States	Medical Center Ophthalmology Associates	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Aerie Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety Tolerability: Number of Ocular and Non-ocular TEAEs	Treatment-emergent adverse events summarized at the subject level by system organ class and preferred term are available in the Adverse Events module. Data reported in the table below corresponds to the total number of participants with ocular and non-ocular treatment-emergent adverse events (TEAEs).	Up to 6 months treatment duration